TOT BIOPHARM Co Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TOT BIOPHARM Co Ltd
Private Company Edition: With $8.9bn raised in the second quarter, venture capital investment in biopharma companies reached its second highest quarterly total to date – behind only Q1 of this year. Also, Nimbus Therapeutics raised $105m and European drug developers get in on the VC action.
Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.
In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.
New $150m Series C round brings Orchard's tally to nearly $300m, just four months after the start-up acquired a portfolio of gene therapy candidates from GSK and eight months after a $110m round. Gritstone closed a Series C then announced an IPO filing, plus more late-summer VC rounds.
- Specialty Pharmaceuticals